Tipranks Press Release.
argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline. The transaction supports argenx's Vision 2030 plan to broaden its presence in autoimmune disease treatment. FB102 is expected to be integrated into argenx's existing research and development programs focused on immunology. For readers who want more ideas in advanced immunology and related technologies, the next step is to explore 134 healthcare AI...
Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline
This is the newest page. Registered accounts read further back.